Publication

Re: "A Case Report of Poor Response to Selpercatinib in the Presence of a 632_633 RET Deletion" by Wijewardene et al.

Authors not recorded

Thyroid2023PMID 37376747PMC10714112stubpubmedPublished

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (7)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 7

cancerMalignant Neoplasmcivic_curation1.00
cancerThyroid Gland Medullary Carcinomacivic_curation1.00
drugSelpercatinibcivic_curation1.00
geneRETcivic_curation1.00
variantRET C618Rcivic_curation1.00
variantRET E632_L633delcivic_curation1.00
variantRET M918Tcivic_curation1.00

Curated evidence

Evidence citing this paper (7)

civicCuratedShowing 1–7 of 7 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
RET Fusion1
Selpercatinib	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	2	submitted	EID12814 Preclinical data demonstrated Ba/F3 cells transformed with KIF5B::RET were IL3 growth independent, and sensitive to selpercatinib with an IC50 of 17.5 +/- 0.7 nM, which the authors considered sensitiv… (full text at CIViC) PMID 37376747 · Szymczak et al., 2023 · Open in CIViC	civic
RET C618R1
Selpercatinib	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	2	accepted	EID11877 Preclinical data demonstrated Ba/F3 cells transformed with RET p.C618R were sensitive to selpercatinib with an IC50 of 3.5nM. PMID 37376747 · Szymczak et al., 2023 · Open in CIViC	civic
RET E632_L633del4
(oncogenic)	Malignant NeoplasmALIAS	Oncogenic	D	Supports Oncogenicity	3	submitted	EID12713 Exogenous expression of RET E632_L633del transformed Ba/F3 cells, causing interleukin-3 independent proliferation. This proliferation was abolished with various RET inhibitors. PMID 37376747 · Szymczak et al., 2023 · Open in CIViC	civic
Pralsetinib	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	2	submitted	EID12815 Ba/F3 cells transformed with E632_L633del showed IL-3 independent growth. Pralsetinib inhibited growth of the cells at IC50 14.9 +/- 1.8 nM. This was similar to the IC50 for selpercatinib, which the a… (full text at CIViC) PMID 37376747 · Szymczak et al., 2023 · Open in CIViC	civic
Selpercatinib	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	3	submitted	EID12712 Ba/F3 cells transformed with E632_L633del showed IL-3 independent growth. Selpercatinib inhibited growth of the cells at approximately 16 nM. This was 4-5 fold higher than the IC50 for RET M918T cells… (full text at CIViC) PMID 37376747 · Szymczak et al., 2023 · Open in CIViC	civic
〃	Thyroid Gland Medullary CarcinomaALIAS	Predictive	B	Supports Sensitivity Response	3	accepted	EID11875 Among 319 medullary thyroid cancer patients enrolled in the LIBRETTO-001 trial, 9 patients harbored the RET p.E632_L633del mutation (c.1894_1899delGAGCTG) in their tumor. After treatment with the sel… (full text at CIViC) PMID 37376747 · Szymczak et al., 2023 · Open in CIViC	civic
RET M918T1
Selpercatinib	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	2	accepted	EID11876 Preclinical data demonstrated Ba/F3 cells transformed with RET p.M918T were sensitive to selpercatinib with an IC50 of 5nM. M918T was included as a positive control for other variants that were being … (full text at CIViC) PMID 37376747 · Szymczak et al., 2023 · Open in CIViC	civic